Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

envista holdings corp. - NVST

NVST

Close Chg Chg %
23.23 0.97 4.15%

Closed Market

24.20

+0.97 (4.15%)

Volume: 3.13M

Last Updated:

Jan 14, 2026, 3:59 PM EDT

Trade Now

Company Overview: envista holdings corp. - NVST

NVST Key Data

Open

$23.05

 Day Range

23.05 - 24.24

52 Week Range

14.23 - 24.24

 Market Cap

$3.84B

Shares Outstanding

164.43M

 Public Float

160.74M

Beta

0.99

 Rev. Per Employee

N/A

P/E Ratio

279.67

 EPS

$0.09

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.12M

  

NVST Performance

1 Week
 
 2.41%
 
1 Month
 
 10.15%
 
3 Months
 
 21.24%
 
1 Year
 
 22.04%
 
5 Years
 
 -32.33%
 

NVST Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About envista holdings corp. - NVST

Envista Holdings Corp. engages in the manufacturing and marketing of dental products, diagnostics, treatment, and trading. It operates through the Specialty Products and Technologies, and Equipment and Consumables segments. The Specialty Products and Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment and Consumables segments develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems, handpieces and associated consumables, treatment units and other dental practice equipment, endodontic systems and related consumables, restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products. It offers dental consumables, equipment, and services to dental professionals. The company was founded in 2018, and is headquartered in Brea, CA.

NVST At a Glance

Envista Holdings Corp.
200 South Kraemer Boulevard
Brea, California 92821
Phone 1-714-817-7000 Revenue 2.51B
Industry Medical Specialties Net Income -1,118,600,000.00
Sector Health Technology Employees 12,300
Fiscal Year-end 12 / 2025
View SEC Filings

NVST Valuation

P/E Current 279.665
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.323
Price to Book Ratio 1.132
Price to Cash Flow Ratio 9.87
Enterprise Value to EBITDA 14.276
Enterprise Value to Sales 1.514
Total Debt to Enterprise Value 0.407

NVST Efficiency

Revenue/Employee 204,113.821
Income Per Employee -90,943.089
Receivables Turnover 6.916
Total Asset Turnover 0.412

NVST Liquidity

Current Ratio 2.035
Quick Ratio 1.761
Cash Ratio 1.217

NVST Profitability

Gross Margin 54.911
Operating Margin 5.70
Pretax Margin -43.205
Net Margin -44.555
Return on Assets -18.377
Return on Equity -31.471
Return on Total Capital -24.955
Return on Invested Capital -22.341

NVST Capital Structure

Total Debt to Total Equity 52.736
Total Debt to Total Capital 34.528
Total Debt to Total Assets 28.395
Long-Term Debt to Equity 47.608
Long-Term Debt to Total Capital 31.17
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Envista Holdings Corp. - NVST

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.51B 2.57B 2.57B 2.51B
Sales Growth
+9.94% +2.40% -0.10% -2.18%
Cost of Goods Sold (COGS) incl D&A
1.04B 1.08B 1.12B 1.13B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
151.90M 162.10M 162.60M 123.10M
Depreciation
69.10M 56.10M 63.00M 40.80M
Amortization of Intangibles
82.80M 106.00M 99.60M 82.30M
COGS Growth
-3.21% +4.34% +3.27% +1.43%
Gross Income
1.47B 1.49B 1.45B 1.38B
Gross Income Growth
+21.55% +1.03% -2.55% -4.96%
Gross Profit Margin
+58.72% +57.93% +56.52% +54.91%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.07B 1.12B 1.13B 1.24B
Research & Development
100.50M 100.10M 93.80M 99.10M
Other SG&A
973.10M 1.02B 1.03B 1.14B
SGA Growth
+7.66% +4.05% +0.76% +9.76%
Other Operating Expense
- - - -
-
Unusual Expense
93.40M 52.10M 321.90M 1.18B
EBIT after Unusual Expense
306.20M 319.20M 3.00M (1.04B)
Non Operating Income/Expense
2.40M 3.10M 5.50M (100.00K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
54.10M 38.40M 63.40M 46.40M
Interest Expense Growth
-13.44% -29.02% +65.10% -26.81%
Gross Interest Expense
54.10M 38.40M 63.40M 46.40M
Interest Capitalized
- - - -
-
Pretax Income
254.50M 283.90M (54.90M) (1.08B)
Pretax Income Growth
+945.51% +11.55% -119.34% -1,875.77%
Pretax Margin
+10.14% +11.05% -2.14% -43.20%
Income Tax
(9.00M) 45.90M 45.30M 33.90M
Income Tax - Current - Domestic
22.10M 51.10M 37.80M 15.40M
Income Tax - Current - Foreign
26.90M 22.40M 44.50M 47.90M
Income Tax - Deferred - Domestic
(500.00K) (38.90M) (33.60M) (38.00M)
Income Tax - Deferred - Foreign
(57.50M) 11.30M (3.40M) 8.60M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
263.50M 238.00M (100.20M) (1.12B)
Minority Interest Expense
- - - -
-
Net Income
263.50M 238.00M (100.20M) (1.12B)
Net Income Growth
+691.29% -9.68% -142.10% -1,016.37%
Net Margin Growth
+10.50% +9.26% -3.90% -44.56%
Extraordinaries & Discontinued Operations
- - - 65.30M
-
Discontinued Operations
- - - 65.30M
-
Net Income After Extraordinaries
328.80M 238.00M (100.20M) (1.12B)
Preferred Dividends
- - - -
-
Net Income Available to Common
328.80M 238.00M (100.20M) (1.12B)
EPS (Basic)
2.0397 1.461 -0.6004 -6.4959
EPS (Basic) Growth
+877.80% -28.37% -141.10% -981.93%
Basic Shares Outstanding
161.20M 162.90M 166.90M 172.20M
EPS (Diluted)
1.8514 1.3401 -0.6004 -6.4959
EPS (Diluted) Growth
+812.47% -27.62% -144.80% -981.93%
Diluted Shares Outstanding
177.60M 177.60M 166.90M 172.20M
EBITDA
551.50M 533.40M 487.50M 266.20M
EBITDA Growth
+45.94% -3.28% -8.61% -45.39%
EBITDA Margin
+21.98% +20.76% +18.99% +10.60%

Snapshot

Average Recommendation HOLD Average Target Price 22.385
Number of Ratings 15 Current Quarters Estimate 0.283
FY Report Date 03 / 2026 Current Year's Estimate 1.272
Last Quarter’s Earnings 0.32 Median PE on CY Estimate N/A
Year Ago Earnings 1.14 Next Fiscal Year Estimate 1.411
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 10 15 14
Mean Estimate 0.28 0.30 1.27 1.41
High Estimates 0.31 0.34 1.38 1.66
Low Estimate 0.25 0.27 1.21 1.31
Coefficient of Variance 6.76 7.35 3.61 6.48

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 2 2 1
HOLD 9 9 9
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Envista Holdings Corp. - NVST

Date Name Shares Transaction Value
Feb 28, 2025 Paul A. Keel Chief Executive Officer; Director 414,439 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Veronica Acurio President, Orthodontics 24,010 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mark E. Nance General Counsel 33,455 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mark E. Nance General Counsel 71,945 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mark E. Nance General Counsel 53,790 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $20.66 per share 1,111,301.40
Feb 28, 2025 Mischa M. Reis SVP, Strategy & Bus. Dev. 19,780 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mischa M. Reis SVP, Strategy & Bus. Dev. 15,615 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mischa M. Reis SVP, Strategy & Bus. Dev. 47,382 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mischa M. Reis SVP, Strategy & Bus. Dev. 38,907 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $20.66 per share 803,818.62
Feb 28, 2025 Paul A. Keel Chief Executive Officer; Director 153,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Paul A. Keel Chief Executive Officer; Director 181,985 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Robert Befidi President, Diagnostics 38,668 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $20.66 per share 798,880.88
Feb 28, 2025 Eric D. Hammes Chief Financial Officer 36,720 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Eric D. Hammes Chief Financial Officer 28,995 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Eric D. Hammes Chief Financial Officer 104,442 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Stefan Nilsson President, Nobel Biocare 24,010 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Stefan Nilsson President, Nobel Biocare 18,960 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Stefan Nilsson President, Nobel Biocare 55,745 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Robert Befidi President, Diagnostics 24,010 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Robert Befidi President, Diagnostics 18,960 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Envista Holdings Corp. in the News